自拟心通1号方防治冠心病支架术后再狭窄的临床研究

Clinical Research on Preventing of No.1 Xintong Prescription( 自拟心通1号方) on ISR

目的:探讨自拟心通1号方预防冠心病患者支架术后再狭窄的临床疗效和安全性,为临床预防工作提供数据支持。方法:将80例接受经皮冠状动脉介入术(PCI)治疗的患者随机分为治疗组和对照组各40例,治疗组予自拟心通1号治疗,对照组予常规处理,随访6个月,通过复查冠状动脉造影术评价再狭窄的发生,并对比治疗前后hs-CRP的变化。结果:PCI术后治疗组6个月再狭窄(ISR)发生率明显低于对照组(P<0.05);治疗后两组hs-CRP均较治疗前降低;治疗后两组比较,治疗组hs-CRP低于对照组(P<0.05)。结论:自拟心通1号方能降低ISR发生率,其作用机制可能与降低hs-CRP水平,抑制炎性反应有关。

Objective： To explore the clinical efficiency and safety of N0.1 Xintong prescription on preventing ISR, providing data support to chnical prevention work. Methods： There were 80 patients accepting PIC, were randomly divided into treatment and control groups, 40 cases in each. Patients were treated by N0.1 Xintong Prescription in treatment group and routine treat- ment in control group, with 6 months follow-up visit. The restenosis was examined and diagnosed based on the result of coro- nary arteriography, and the state of hs-CRP was compared before and after treatment. Results： The treatment group showed low- er occurrence rate of ISR than the control group obviously （P〈0.05）, 6 months after PIC. The state of hs-CRP was decreased in two groups, and the treatment group showed lower state of hs-CRP than the control group （P〈0.05）, after treatment. Conclusion： The N0.1 Xintong prescription can low the occurrence rate of ISR, the mechanism of which may be connecting with the de- creasing of hs-CRP level and restraining the inflammatory reaction.